- Home
- FHI vs AKRO Comparison
FHI vs AKRO Comparison
Compare FHI & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHI
- AKRO
- Stock Information
- Founded
- FHI 1955
- AKRO 2017
- Country
- FHI United States
- AKRO United States
- Employees
- FHI N/A
- AKRO N/A
- Industry
- FHI Investment Managers
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- FHI Finance
- AKRO Health Care
- Exchange
- FHI Nasdaq
- AKRO Nasdaq
- Market Cap
- FHI 4.0B
- AKRO 3.7B
- IPO Year
- FHI N/A
- AKRO 2019
- Fundamental
- Price
- FHI $53.39
- AKRO $46.49
- Analyst Decision
- FHI Buy
- AKRO Strong Buy
- Analyst Count
- FHI 7
- AKRO 8
- Target Price
- FHI $47.86
- AKRO $80.38
- AVG Volume (30 Days)
- FHI 653.5K
- AKRO 1.2M
- Earning Date
- FHI 10-30-2025
- AKRO 11-07-2025
- Dividend Yield
- FHI 2.57%
- AKRO N/A
- EPS Growth
- FHI 53.50
- AKRO N/A
- EPS
- FHI 4.52
- AKRO N/A
- Revenue
- FHI $1,681,523,000.00
- AKRO N/A
- Revenue This Year
- FHI $7.41
- AKRO N/A
- Revenue Next Year
- FHI $4.73
- AKRO N/A
- P/E Ratio
- FHI $11.70
- AKRO N/A
- Revenue Growth
- FHI 5.55
- AKRO N/A
- 52 Week Low
- FHI $35.05
- AKRO $21.34
- 52 Week High
- FHI $54.42
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- FHI 58.17
- AKRO 47.87
- Support Level
- FHI $51.22
- AKRO $45.20
- Resistance Level
- FHI $53.09
- AKRO $47.40
- Average True Range (ATR)
- FHI 0.75
- AKRO 1.46
- MACD
- FHI -0.00
- AKRO 0.06
- Stochastic Oscillator
- FHI 91.99
- AKRO 34.90
About FHI Federated Hermes Inc.
Federated Hermes provides asset-management services for institutional and individual investors. The firm had $843.7 billion in managed assets at the end of June 2025, composed of equity (10%), multi-asset (less than 1%), fixed-income (12%), alternative (2%), and money market (75%) funds. The firm's cash-management operations are expected to generate around 52% of Federated's revenue this year, compared with 29%, 11%, and 8%, respectively, for the equity, fixed-income, and alternatives/multi-asset/other operations. The company's products are distributed via trust banks, wealth managers, and retail broker/dealers (67% of AUM), institutional investors (26%), and international clients (7%).
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.